Correlación clínico-histopatológica del cáncer de próstata clínicamente localizado y la angiogénesis

Contenido principal del artículo

José Gadu Campos Salcedo
Jesús Javier Torres Salazar
Mariana Aragón Flores
Antonio Ricardez Espinosa
David J. Pacheco Bouthillier

Resumen

El cáncer de próstata es la neoplasia maligna más común en el hombre y su tipificación es limitada.

Detalles del artículo

Cómo citar
1.
Correlación clínico-histopatológica del cáncer de próstata clínicamente localizado y la angiogénesis. RSM [Internet]. 2024 Dec. 17 [cited 2025 Feb. 19];61(1). Available from: https://revistasanidadmilitar.org/index.php/rsm/article/view/2031
Sección
Artículos de investigación

Cómo citar

1.
Correlación clínico-histopatológica del cáncer de próstata clínicamente localizado y la angiogénesis. RSM [Internet]. 2024 Dec. 17 [cited 2025 Feb. 19];61(1). Available from: https://revistasanidadmilitar.org/index.php/rsm/article/view/2031

Referencias

Brawer MK. Quantitative microvessel density: A staging and prognostic marker for human prostatic carcinoma. Cancer 1996; 78:

-9.

Singh H, Dang TD, Ayala GE, Rowley DR. Transforming growth factor-?1 induced myofibroblasts regulate LNCaP cell death. J Urol 2004;

: 2421-5.

Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by andro- gens in hormone responsive human prostate carcinoma: evidence for an- drogen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688-93.

Trojan L, Michel MS, Rensh F, Hackson DG, Alken P, Grobholz R. Lymph lad blood vessel architecture in benign and malignant prostatic tissue: lack of lympohangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J Urol 2004; 172: 103-7.

Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Amer J Path 1993; 143: 401.

Xin Hua Liu. Inhibition of cicloooxigenase -2 Supresses angioge- nesis and the growth of prostate cancer in vivo. J Urol; 164: 820-5.

Scardino y cols. Photodinamic therapy with Tookad®, for the focal treatment of prostate cancer 21st Congress of the European Association of Urology. Paris 2006.

Chung LWK, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: the missing link of tumor microenviron- ment. J Urol 2005; 173: 10-20.

Ferrer. Vascular endothelial growth factor (VEGF) expression inhuman prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997; 157: 2329-33.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285-1182

Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase com- plex (ABC) in inmunoperoxidase techniques: a comparison between ABC

and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.

Izawa JI, Dinney CPN. The role of angiogenesis in prostate and other urologic cancers: a review. Can Med Assoc J 2001; 164(5): 662-

Liu XH, Kirchenbaum A. Inhibition of cyclooxygenase-2 supres- se angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;

: 820-5.

Moy YP, Sessa WC, Weiss RM. Inhibition of angiogenesis and tumor growth in human prostate cancer LNCaP cells with the inhibition of endothelial nitric oxid. J Urol 1999; 161(4S): 130.

Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angio- genesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the pros- tate. Cancer 1997; 79: 772-9.

Artículos similares

También puede Iniciar una búsqueda de similitud avanzada para este artículo.

Artículos más leídos del mismo autor/a

1 2 > >>